Citigroup Inc Opti Nose, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Opti Nose, Inc. stock. As of the latest transaction made, Citigroup Inc holds 161,576 shares of OPTN stock, worth $77,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares

161,576

Previous 32,273 400.65%

Holding current value

$77,556

Previous $33,000 227.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.67 - $1.27 $86,633 - $164,214	129,303 Added 400.65%	161,576 $108,000
Q2 2024 Aug 12, 2024	BUY	$0.82 - $1.44 $18,126 - $31,831	22,105 Added 217.4%	32,273 $33,000
Q1 2024 May 10, 2024	SELL	$1.17 - $1.94 $283 - $469	-242 Reduced 2.32%	10,168 $14,000
Q4 2023 Feb 09, 2024	BUY	$1.02 - $1.47 $9,261 - $13,347	9,080 Added 682.71%	10,410 $13,000
Q3 2023 Nov 09, 2023	SELL	$0.93 - $1.38 $41,089 - $60,971	-44,182 Reduced 97.08%	1,330 $1,000
Q2 2023 Aug 10, 2023	SELL	$1.11 - $2.05 $119,073 - $219,909	-107,273 Reduced 70.21%	45,512 $55,000
Q1 2023 May 11, 2023	SELL	$1.63 - $2.02 $13,946 - $17,283	-8,556 Reduced 5.3%	152,785 $294,000
Q4 2022 Feb 09, 2023	BUY	$1.68 - $3.7 $249,466 - $549,420	148,492 Added 1155.67%	161,341 $298,000
Q3 2022 Nov 10, 2022	BUY	$3.43 - $4.01 $39,932 - $46,684	11,642 Added 964.54%	12,849 $47,000
Q2 2022 Aug 10, 2022	SELL	$1.76 - $3.82 $908 - $1,971	-516 Reduced 29.95%	1,207 $4,000
Q1 2022 May 12, 2022	SELL	$1.77 - $2.93 $1,254 - $2,077	-709 Reduced 29.15%	1,723 $4,000
Q4 2021 Feb 10, 2022	BUY	$1.55 - $3.1 $3,769 - $7,539	2,432 New	2,432 $4,000

Others Institutions Holding OPTN

# of Institutions

Shares Held

88.3M

Call Options Held

Put Options Held

View Full List

About OptiNose, Inc.

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $40M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

More about OPTN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account